Urgent.News

What's breaking now, across hundreds of outlets.

Health & Medicine

FDA again turns back Capricor Duchenne cell therapy

In an unusual statement, the FDA accused Capricor of “serious data integrity violations” that compromised its study findings and led to deramiocel’s second rejection since 2025.

We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.

This story

This is one outlet's version. Read the fullest account.

Every outlet that reported this, and when →

Read the original at biopharmadive.com →

Report a problem with this story

More in Health & Medicine

More from Saturday 21 November →